Michael Powell - 12 Sep 2024 Form 3 Insider Report for Bicara Therapeutics Inc. (BCAX)

Reporting relationship: Director
Issuer ticker: BCAX
Reported as of: 12 Sep 2024
Net transaction value: $0
SEC form: 3
Accepted by SEC: 12 Sep 2024, 21:16:42 UTC
Prior SEC filing: 16 Jun 2023
Next SEC filing: 10 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Lara Meisner, Attorney-in-Fact

Key filing fact

Michael Powell filed Form 3 for Bicara Therapeutics Inc. (BCAX) on 12 Sep 2024.

Key facts

This page summarizes Michael Powell's Form 3 filing for Bicara Therapeutics Inc. (BCAX).
0 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 12 Sep 2024, 21:16.

Change

Previous filing in this sequence was filed on 16 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BCAX holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 12 Sep 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 59,501
Exercise price: $9.24
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares underlying this option vest in sixteen equal quarterly installments following August 6, 2024, subject to the Reporting Person's continued service on each such vesting date.

SEC remarks

Exhibit 24 - Power of Attorney